Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

GVL effect in plasmacytoid DC leukemia/lymphoma

Bone Marrow Transplantation volume 45, pages 961–962 (2010)Cite this article

According to the WHO–EORTC classification, plasmacytoid DC (pDC) leukemia/lymphoma represents a discrete entity with characteristic biological and clinical features.1, 2 Despite high response rates with intensified induction therapy, relapse is frequent, allo-SCT increases the chance of long-term survival.3, 4

Reimer et al.4 reported that allo-SCT resulted in lower relapse rate compared with autotransplantation, but this benefit was offset by the high mortality rate of the allo-SCT procedure. A reduced-intensity allograft represents a safe and effective approach for patients not eligible for myeloablative conditioning, but its success is dependent upon GVL.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

References

  1. Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH et al. WHO-EORTC classification for cutaneus lymphomas. Blood 2005; 105: 3678–3685.

    Article  Google Scholar 

  2. Garnache-Ottou F, Feuillard J, Saas P . Plasmacytoid dendritic cell leukaemia/lymphoma: towards a well defined entity? Br J Haematol 2007; 136: 539–548.

    Article  CAS  PubMed  Google Scholar 

  3. Feuillard J, Jacob MC, Valenci F, Maynadiè M, Gressin R, Chaperot L et al. Clinical and biologic features of CD4+ CD 56+ malignancies. Blood 2002; 99: 1556–1563.

    Article  CAS  PubMed  Google Scholar 

  4. Reimer P, Rüdiger T, Kraemer D, Kunzmann V, Weissinger F, Zettl A et al. What is CD4+ CD56+ malignancy and how should it be treated? Bone Marrow Transplant 2003; 32: 637–646.

    Article  CAS  PubMed  Google Scholar 

  5. Schmid C, Labopin M, Nagler A, Bornhäuser M, Finke J, Fassas A et al. Donor lymphocyte Infusion in the treatment of first haematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukaemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. J Clin Oncol 2007; 25: 4938–4945.

    Article  CAS  PubMed  Google Scholar 

  6. Ghaperot L, Bendriss N, Manches O, Gressin R, Maynadie M, Trimoreau F et al. Identification of a leukemic counterpart of the plasmacytoid dendritic cells. Blood 2001; 97: 3210–3217.

    Article  Google Scholar 

  7. Chaperot L, Perrot I, Jacob MC, Blanchard D, Salaun V, Deneys V et al. Leukemic plasmacytoid dendritic cells share phenotypic and functional features with their normal counterparts. Eur J Immunol 2004; 34: 418–426.

    Article  CAS  PubMed  Google Scholar 

  8. Hanabuchi S, Watanabe N, Wang YH, Wang YH, Ito T, Shaw J et al. Human plasmacytoid predendritic cells activate NK cells through glucocorticoid-induced tumor necrosis factor receptor-ligand (GITRL). Blood 2006; 107: 3617–3623.

    Article  CAS  PubMed  Google Scholar 

  9. Naranjo-Gómez M, Oliva H, Climent N, Fernàndez MA, Ruiz-Riol M, Bofill M et al. Expression and function of IL-2 receptor in activated human plasmatoid dendritic cells. Eur J Immunol 2007; 37: 1764–1772.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology–BMT Unit, George Papanicolaou Hospital, Thessaloniki, Greece

    P Kaloyannidis, C Vadikoliou, D Mallouri, L Sakkas & I Sakellari

  2. ‘Attikon’ University Hospital, Athens, Greece

    A Zomas

  3. Department of Immunology, ‘G.Gennimatas’ Hospital, Athens, Greece

    G Paterakis

Authors
  1. P Kaloyannidis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A Zomas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G Paterakis
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C Vadikoliou
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D Mallouri
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. L Sakkas
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. I Sakellari
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P Kaloyannidis.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kaloyannidis, P., Zomas, A., Paterakis, G. et al. GVL effect in plasmacytoid DC leukemia/lymphoma. Bone Marrow Transplant 45, 961–962 (2010). https://doi.org/10.1038/bmt.2009.270

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2009.270

This article is cited by

Search

Advanced search

Quick links